Gan HK - Search Results

1

Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents.

Le Tourneau C, Gan HK, Razak AR, Paoletti X. Le Tourneau C, et al. Among authors: gan hk. PLoS One. 2012;7(12):e51039. doi: 10.1371/journal.pone.0051039. Epub 2012 Dec 12. PLoS One. 2012. PMID: 23251419 Free PMC article.

2

Development of anti-cancer drugs.

Arrondeau J, Gan HK, Razak AR, Paoletti X, Le Tourneau C. Arrondeau J, et al. Among authors: gan hk. Discov Med. 2010 Oct;10(53):355-62. Discov Med. 2010. PMID: 21034677 Free article. Review.

3

Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.

Le Tourneau C, Razak AR, Gan HK, Pop S, Diéras V, Tresca P, Paoletti X. Le Tourneau C, et al. Among authors: gan hk. Eur J Cancer. 2011 Jul;47(10):1468-75. doi: 10.1016/j.ejca.2011.03.016. Epub 2011 Apr 7. Eur J Cancer. 2011. PMID: 21482105 Review.

4

Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland.

Le Tourneau C, Razak AR, Levy C, Calugaru V, Galatoire O, Dendale R, Desjardins L, Gan HK. Le Tourneau C, et al. Among authors: gan hk. Br J Ophthalmol. 2011 Nov;95(11):1483-9. doi: 10.1136/bjo.2010.192351. Epub 2010 Dec 22. Br J Ophthalmol. 2011. PMID: 21183517 Review.

5

Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma.

Gougis P, Moreau Bachelard C, Kamal M, Gan HK, Borcoman E, Torossian N, Bièche I, Le Tourneau C. Gougis P, et al. Among authors: gan hk. JNCI Cancer Spectr. 2019 Nov 12;3(4):pkz055. doi: 10.1093/jncics/pkz055. eCollection 2019 Dec. JNCI Cancer Spectr. 2019. PMID: 32337482 Free PMC article.

6

Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.

Le Tourneau C, Michiels S, Gan HK, Siu LL. Le Tourneau C, et al. Among authors: gan hk. J Clin Oncol. 2009 Dec 10;27(35):5965-71. doi: 10.1200/JCO.2009.22.3685. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805677 Review.

7

Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.

Gan HK, You B, Pond GR, Chen EX. Gan HK, et al. J Natl Cancer Inst. 2012 Apr 18;104(8):590-8. doi: 10.1093/jnci/djs141. Epub 2012 Apr 6. J Natl Cancer Inst. 2012. PMID: 22491345 Review.

8

Inclusion of elderly patients in oncology clinical trials.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J. Le Saux O, et al. Among authors: gan hk. Ann Oncol. 2016 Sep;27(9):1799-804. doi: 10.1093/annonc/mdw259. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358382 Free article.

9

Changes in the use of end points in clinical trials for elderly cancer patients over time.

Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J. Le Saux O, et al. Among authors: gan hk. Ann Oncol. 2017 Oct 1;28(10):2606-2611. doi: 10.1093/annonc/mdx354. Ann Oncol. 2017. PMID: 28961850 Free article.

10

The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.

Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J. Maillet D, et al. Among authors: gan hk. Ann Oncol. 2016 Jan;27(1):192-8. doi: 10.1093/annonc/mdv485. Epub 2015 Oct 19. Ann Oncol. 2016. PMID: 26483049 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

143 results

Search Page

Filters